FDA Seeks Input On Inactive Ingredients Database
US Agency Plans To Prioritize Maximum Daily Exposure Information
Executive Summary
Industry input is being sought by the FDA on its inactive ingredient database, as the US agency considers how to prioritize the addition of maximum daily exposure limits as well as mulling the removal of specific dosage form information.
You may also be interested in...
Sen. Burr Worries Rising User Fees Helping US FDA Evade Congressional Oversight
Burr wants more FDA accountability in the new user fee agreements and questions whether they benefit patients. Generic approval modifications get attention at hearing.
Sen. Burr Worries Rising User Fees Helping US FDA Evade Congressional Oversight
Burr wants more FDA accountability in the new user fee agreements and questions whether they benefit patients. Generic approval modifications get attention at hearing.
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.